Vaccines against respiratory viral infections are likely to lack full efficacy in the most vulnerable aged population group. In this project we develop a yeast-based, cost-effective and highly scalable prototyping-and manufacturing technology for highly potent virus-neutralizing VHH-Fc anitbodies with
engineered prolonged halflife. Such passive immunization strategy complements vaccination-based approaches during peak periods of infection risk. This technology complements the antibody discovery
efforts that are ongoing in collaboration with the Saelens lab.